SenzaGen agrees to acquire UK's Alcyomics for initial SEK 28 million

Bitget2026/10/28 18:41

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

SenzaGen agreed to acquire 100% of UK non-animal immunotoxicology specialist Alcyomics for an initial GBP 2.12 million in cash.
Two potential cash earn-outs are capped at GBP 0.83 million for performance milestones and GBP 1.05 million for net-debt reduction.
Completion is expected around November 4, 2026, expanding the group's non-animal testing offering into preclinical drug development.
Funding combines existing cash with SEK 25 million of convertible bonds issued to principal owner Eiffel Investment Group, carrying 5.5% annual interest.
Alcyomics' revenue rose 46% to approximately GBP 1.49 million in fiscal 2025/2026, with an EBITDA margin of approximately 24%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SenzaGen AB published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

SenzaGen agrees to acquire UK's Alcyomics for initial SEK 28 million

You may also like

Crypto prices